Magnesium

Identification

Name
Magnesium
Accession Number
DB01378
Type
Small Molecule
Groups
Approved, Nutraceutical
Description

Magnesium hydroxide is used primarily in "Milk of Magnesia", a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Magnesium acetate0E95JZY48K142-72-3UEGPKNKPLBYCNK-UHFFFAOYSA-L
Magnesium lactateMT6QI8324A18917-93-6VCCUEOJOYXPBRA-UHFFFAOYSA-L
Magnesium levulinateDU3I0H5Z4H58505-81-0RECCGACJWKEPOU-UHFFFAOYSA-L
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Magnesium 250 mgTablet250 mgOralLeiner Health ProductsNot applicableNot applicableCanada
Magnesium Lactate Cap 70mgCapsule70 mgOralStandard Process Inc.Not applicableNot applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acti Mag 250 CapletTablet250 mgOralActi Form Ltd.1991-12-312005-03-21Canada
Chelated Magnesium 150mg - TabTablet150 mgOralHealth Wise Nutrition Inc.1997-08-152000-07-29Canada
Chelated Magnesium Supplement - Tab 100mgTablet100 mgOralAlbion1996-09-062007-10-19Canada
Chelated Magnesium Tab 50mgTablet50 mgOralJamieson Laboratories Ltd1975-12-312001-09-14Canada
Chelazome Magnesium 100mgTablet100 mgOralTrophic Canada Ltd.1987-12-312000-08-03Canada
F.M. FormulaCapsule80 mgOralNatures Sunshine Products, Inc.1999-05-252009-08-07Canada
MagnelisCapsule165 mgOralImport Export SantÉ Nature Inc.1999-02-202003-08-01Canada
MagnesiumCapsule20 mgOralFrega Inc.1981-12-312008-02-13Canada
Magnesium - 100mg TabTablet100 mgOralMetagenics, Inc.1997-02-012008-08-28Canada
Magnesium 150 mgCapsule150 mgOralPreferred Nutrition Inc.2004-05-122005-08-04Canada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NMC Magma Mineral PackPlaster3 g/100gTopicalNmc (Natural Magma Cosmetics)2013-07-08Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acetabolan III Vitamin and Mineral SupplementMagnesium (112.5 mg) + Pyridoxine hydrochloride (2.63 mg) + Vitamin C (250.0 mg) + Zinc (7.5 mg)CapsuleOralIovate Health Sciences International Inc.2003-12-052007-07-18Canada
Acetabolan-II Vitamin and Mineral SupplementMagnesium (90 mg) + Pyridoxine hydrochloride (2.1 mg) + Vitamin C (200 mg) + Zinc (6 mg)CapsuleOralIovate Health Sciences International Inc.2000-11-202005-06-21Canada
Acti-cal/mag 2:1 + Zinc and D CapletMagnesium (175.0 mg) + Calcium (350.0 mg) + Cholecalciferol (100 unit) + Zinc (6.0 mg)TabletOralActi Form Ltd.1991-12-312005-03-21Canada
Actical Plus Calcium-magnesium-vitamin D3-silicon ChewableMagnesium (100 mg) + Calcium (200 mg) + Cholecalciferol (100 unit) + Silicon (2 mg)TabletOralUsana Health Sciences, Inc.1999-09-302004-07-27Canada
Active Calcium Plus Magnesium, Vitamin D and SiliconMagnesium (100 mg) + Calcium (200 mg) + Cholecalciferol (100 unit) + Silicon (2.25 mg)TabletOralUsana Health Sciences, Inc.2002-07-082007-07-18Canada
ActyformMagnesium (61.15 mg) + Copper (1 mg) + Iron (4.18 mg) + Zinc (9 mg)CapsuleOralTechnodiet S.E.N.C.1999-10-262008-08-13Canada
AlphaligoMagnesium (119 mg) + Cyanocobalamin (10 mcg) + Manganese (4.5 mg) + Potassium (112.5 mg) + Sodium phosphate (125 mg)TabletOralClinique Lafontaine Inc, Division Les Importations Ortho1998-03-062008-08-07Canada
AminosynMagnesium acetate (21 mg/100mL) + Glycine (448 mg/100mL) + Histidine (105 mg/100mL) + L-Alanine (448 mg/100mL) + L-Arginine (343 mg/100mL) + L-Isoleucine (252 mg/100mL) + L-Leucine (329 mg/100mL) + L-Lysine acetate (252 mg/100mL) + L-Methionine (140 mg/100mL) + L-Phenylalanine (154 mg/100mL) + L-Proline (300 mg/100mL) + L-Threonine (182 mg/100mL) + L-Tryptophan (56 mg/100mL) + L-Tyrosine (31 mg/100mL) + L-Valine (280 mg/100mL) + Phosphoric acid (40 mg/100mL) + Potassium acetate (128 mg/100mL) + Serine (147 mg/100mL) + Sodium Chloride (234 mg/100mL)Injection, solutionIntravenousHospira, Inc.2011-03-23Not applicableUs
Aminosyn 3.5% MMagnesium acetate (21 mg) + Glycine (448 mg) + Histidine (105 mg) + L-Alanine (448 mg) + L-Arginine (343 mg) + L-Isoleucine (252 mg) + L-Leucine (329 mg) + L-Lysine acetate (252 mg) + L-Methionine (140 mg) + L-Phenylalanine (154 mg) + L-Proline (300 mg) + L-Threonine (182 mg) + L-Tryptophan (56 mg) + L-Tyrosine (31 mg) + L-Valine (280 mg) + Potassium acetate (128 mg) + Serine (147 mg) + Sodium Chloride (234 mg)LiquidIntravenousAbbott1980-12-311999-08-09Canada
ArmaxMagnesium (50 mg) + Manganese (1.5 mg) + Niacin (15 mg) + Nicotinamide (150 mg) + Calcium pantothenate (50 mg) + Vitamin C (15 mg) + Zinc (1.5 mg)TabletOralEnzymatic Therapy, Inc.1997-03-202001-08-02Canada
Categories
UNII
T6V3LHY838
CAS number
7439-95-4
Weight
Average: 24.305
Monoisotopic: 23.985041898
Chemical Formula
Mg
InChI Key
JLVVSXFLKOJNIY-UHFFFAOYSA-N
InChI
InChI=1S/Mg/q+2
IUPAC Name
magnesium(2+) ion
SMILES
[Mg++]

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
USodium/potassium-transporting ATPase subunit alpha-1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Tyrosine MetabolismMetabolic
Inositol MetabolismMetabolic
GlycolysisMetabolic
Nicotinate and Nicotinamide MetabolismMetabolic
Folate MetabolismMetabolic
Citric Acid CycleMetabolic
Pravastatin Action PathwayDrug action
Risedronate Action PathwayDrug action
2-Hydroxyglutric Aciduria (D And L Form)Disease
AICA-RibosiduriaDisease
Glutaric Aciduria Type IDisease
Leigh SyndromeDisease
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)Disease
HypercholesterolemiaDisease
Sialuria or French Type SialuriaDisease
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase DeficiencyDisease
Esmolol Action PathwayDrug action
Metoprolol Action PathwayDrug action
Propranolol Action PathwayDrug action
Disopyramide Action PathwayDrug action
Phenytoin (Antiarrhythmic) Action PathwayDrug action
Flecainide Action PathwayDrug action
Intracellular Signalling Through LHCGR Receptor and Luteinizing Hormone/ChoriogonadotropinSignaling
Hyperinsulinism-Hyperammonemia SyndromeDisease
Metachromatic Leukodystrophy (MLD)Disease
Nifedipine Action PathwayDrug action
Mercaptopurine Action PathwayDrug action
Thioguanine Action PathwayDrug action
Refsum DiseaseDisease
Hyperglycinemia, non-ketoticDisease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

Synthesis Reference

David S. Thompson, John S. Prestley, Jr., Thomas E. Webb, "Aluminum-magnesium alloys sheet exhibiting improved properties for forming and method aspects of producing such sheet." U.S. Patent US4151013, issued 0000.

US4151013
General References
Not Available
External Links
Human Metabolome Database
HMDB00547
KEGG Compound
C00305
PubChem Compound
888
PubChem Substance
46508750
ChemSpider
865
BindingDB
15
ChEBI
18420
Therapeutic Targets Database
DCL000876
PharmGKB
PA164712884
HET
MG
Wikipedia
Magnesium
ATC Codes
A12CC07 — Magnesium levulinateA12CC06 — Magnesium lactate
AHFS Codes
  • 88:29.00* — Minerals
  • 88:28.00 — Multivitamin Preparations
PDB Entries
101d / 109d / 119d / 121p / 13pk / 146d / 150d / 159d / 184d / 1a05
show 12600 more
MSDS
Download (73.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionPaclitaxel-induced Neuropathy1
1CompletedPreventionBone destruction1
1, 2CompletedSupportive CareHypertensive / Pre-Hypertension1
1, 2CompletedTreatmentTemporomandibular Joint Disorders1
1, 2Not Yet RecruitingTreatmentArterial Hypertension / Diabetes / Hypokalaemia / Hyponatremias1
2CompletedPreventionNoise Induced Hearing Loss1
2CompletedPreventionPremature Atrial Contraction1
2CompletedSupportive CareIdiopathic Scoliosis1
2CompletedTreatmentAsthma Bronchial1
2CompletedTreatmentCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Neurologic Manifestations1
2CompletedTreatmentIntubation Conditions1
2CompletedTreatmentScoliosis1
2Not Yet RecruitingPreventionNeuropathic Pain Induced by Mastectomy1
2Not Yet RecruitingTreatmentChronic Kidney Disease (CKD) / Dialysis related complications / End Stage Renal Disease (ESRD)1
2RecruitingTreatmentDelayed Onset Muscle Soreness, DOMS1
2Unknown StatusTreatmentAdenocarincoma of Pancreas / Stage III Pancreatic Cancer / Stage IVA Pancreatic Cancer / Stage IVB Pancreatic Cancer1
2, 3CompletedTreatmentPain1
2, 3Unknown StatusTreatmentPancreatitis1
3CompletedTreatmentCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Infarction (MI) / Myocardial Ischemia1
3CompletedTreatmentNeoplasms, Colorectal1
3Not Yet RecruitingTreatmentAlcohol Withdrawal Syndrome(AWS)1
3Not Yet RecruitingTreatmentCervical Cancers1
3Not Yet RecruitingTreatmentThrombotic Thrombocytopenic Purpura (TTP)1
3RecruitingPreventionExtreme Immaturity / Magnesium Deficiency / Premature Births1
3TerminatedTreatmentCoronary Artery Disease / Valvular Heart Disease1
3TerminatedTreatmentPremature Labour1
3TerminatedTreatmentRadiation-induced Oesophagitis1
4CompletedPreventionIntracranial Hemorrhages / Ischemia, Brain / Periventricular Leukomalacia / Premature Births1
4CompletedPreventionLiving Donor Liver Transplantation / Reperfusion Injury1
4CompletedTreatmentAlcohol-Induced Disorders1
4CompletedTreatmentHyperemesis Gravidarum / Morning Sickness / Nausea / Pregnancy / Vomiting1
4CompletedTreatmentAdjunct to general anesthesia therapy / Intravenous Anesthesia1
4CompletedTreatmentPatient With Neuropathic Pain1
4CompletedTreatmentPostoperative pain1
4CompletedTreatmentPre-eclampsia Aggravated1
4CompletedTreatmentPregnancy1
4Not Yet RecruitingSupportive CareArthritis Knee / Dexmedetomidine / Magnesium Sulfate1
4RecruitingPreventionAcute Kidney Injury (AKI)1
4RecruitingTreatmentDeep Neuromuscular Blockade / Magnesium Sulfate / Neuromuscular Blockade / Rocuronium1
4TerminatedTreatmentMagnesium Sulphate / Pain / Post Pulmonary Resection1
Not AvailableCompletedNot AvailableThyroid Cancers1
Not AvailableCompletedPreventionHypomagnesaemia1
Not AvailableCompletedPreventionNonvalvular Atrial Fibrillation1
Not AvailableCompletedTreatmentAsthma Bronchial1
Not AvailableEnrolling by InvitationPreventionPostoperative pain1
Not AvailableRecruitingPreventionEmergence Delirium1
Not AvailableTerminatedTreatmentPrimary Hypomagnesemia (Disorder)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral250 mg
Injection, solutionIntravenous
CapsuleOral
WaferOral
TabletOral150 mg
TabletOral50 mg
Tablet, extended releaseOral
Tablet, effervescentOral
Tablet, chewableOral
CapsuleOral80 mg
Capsule, gelatin coatedOral
Capsule, liquid filledOral
PowderOral
LiquidOral
SolutionIntravenous
LiquidIntravenous
CapsuleOral165 mg
TabletOral100 mg
CapsuleOral72.5 mg
CapsuleOral125 mg
CapsuleOral250 mg
CapsuleOral100 mg
CapsuleOral90 mg
CapsuleOral150 mg
TabletOral300 mg
CapsuleOral70 mg
LiquidOral114 mg
PowderOral240 mg
TabletOral252 mg
TabletOral70 mg
SolutionOral118.6 mg
TabletOral200 mg
LiquidOral23.92 mg
PowderOral119.6 mg
LiquidOral1 g
CapsuleOral20 mg
TabletOral
Granule, effervescentOral
TabletOral36 mg
PlasterTopical3 g/100g
Injection, solution, concentrateIntravenous
LiquidOral10.24 mg
TabletOral188 mg
TabletOral375 mg
Tablet, delayed releaseOral64 mg
Tablet, coatedOral
Powder, for solutionOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)651 °CPhysProp
boiling point (°C)1100 °CPhysProp
Predicted Properties
PropertyValueSource
logP-0.57ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8382
Blood Brain Barrier+0.9708
Caco-2 permeable+0.7056
P-glycoprotein substrateNon-substrate0.8831
P-glycoprotein inhibitor INon-inhibitor0.9869
P-glycoprotein inhibitor IINon-inhibitor0.9855
Renal organic cation transporterNon-inhibitor0.9176
CYP450 2C9 substrateNon-substrate0.8465
CYP450 2D6 substrateNon-substrate0.823
CYP450 3A4 substrateNon-substrate0.8094
CYP450 1A2 substrateNon-inhibitor0.8824
CYP450 2C9 inhibitorNon-inhibitor0.9221
CYP450 2D6 inhibitorNon-inhibitor0.9555
CYP450 2C19 inhibitorNon-inhibitor0.9469
CYP450 3A4 inhibitorNon-inhibitor0.9846
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9015
Ames testNon AMES toxic0.9663
CarcinogenicityCarcinogens 0.6381
BiodegradationReady biodegradable0.9031
Rat acute toxicity2.0881 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9462
hERG inhibition (predictor II)Non-inhibitor0.9716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as homogeneous alkaline earth metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a alkaline earth metal atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous metal compounds
Class
Homogeneous alkaline earth metal compounds
Sub Class
Not Available
Direct Parent
Homogeneous alkaline earth metal compounds
Alternative Parents
Not Available
Substituents
Homogeneous alkaline earth metal
Molecular Framework
Not Available
External Descriptors
monoatomic dication, divalent metal cation, magnesium cation (CHEBI:18420) / a cation (MG+2)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Buchachenko AL, Kuznetsov DA, Berdinskii VL: [New mechanisms of biological effects of electromagnetic fields]. Biofizika. 2006 May-Jun;51(3):545-52. [PubMed:16808357]
  2. Sirijovski N, Olsson U, Lundqvist J, Al-Karadaghi S, Willows RD, Hansson M: ATPase activity associated with the magnesium chelatase H-subunit of the chlorophyll biosynthetic pathway is an artefact. Biochem J. 2006 Dec 15;400(3):477-84. [PubMed:16928192]
  3. Balasubramaniyan V, Nalini N: Leptin alters brain adenosine triphosphatase activity in ethanol-mediated neurotoxicity in mice. Singapore Med J. 2006 Oct;47(10):864-8. [PubMed:16990961]
  4. Nogovitsina OR, Levitina EV: Neurological aspects of the clinical features, pathophysiology, and corrections of impairments in attention deficit hyperactivity disorder. Neurosci Behav Physiol. 2007 Mar;37(3):199-202. [PubMed:17294093]

Drug created on July 06, 2007 14:30 / Updated on November 13, 2017 21:50